TC Medical(SH:600763) Sou Hu Cai Jing·2025-10-15 11:37Core Viewpoint - Tongce Medical (600763) shows a slight increase in stock price and mixed capital flow, indicating potential investor interest despite some outflows from major funds [1][2]. Financial Performance - As of the latest report, Tongce Medical's total revenue for the first half of 2025 reached 1.448 billion yuan, a year-on-year increase of 2.68% [3]. - The net profit attributable to shareholders was 321 million yuan, up 3.67% year-on-year, while the net profit excluding non-recurring items was 317 million yuan, increasing by 3.85% [3]. - The company's second-quarter revenue was 704 million yuan, reflecting a 0.24% year-on-year growth, with a net profit of 137 million yuan, up 0.44% year-on-year [3]. Market Position - Tongce Medical's total market capitalization is 19.605 billion yuan, ranking 8th in the medical services industry [3]. - The company has a price-to-earnings ratio of 30.52, significantly lower than the industry average of 83.4, indicating a potentially undervalued stock [3]. - The gross margin stands at 40.75%, higher than the industry average of 35.92%, showcasing operational efficiency [3]. Capital Flow Analysis - On October 15, 2025, the stock experienced a net outflow of 7.0293 million yuan from major funds, accounting for 3.61% of the total transaction volume [2]. - Retail investors contributed a net inflow of 1.8809 million yuan, representing 0.97% of the total transaction volume, indicating some retail interest [1][2]. Analyst Ratings - Over the past 90 days, 9 institutions have rated the stock, with 7 buy ratings and 2 hold ratings, suggesting a generally positive outlook [4]. - The average target price set by analysts is 5.201 yuan, indicating potential upside from the current trading price [4].